Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

165
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
165
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

571
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
571
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

404
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
404
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

68
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
68
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

755
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
755
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

701
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
701

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sensitivity and specificity of drug interaction databases to detect interactions with recently approved oral antineoplastics.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2021
Same author

Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2020
Same author

International usage of an English language oncology pharmacy podcast.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2020
Same author

Peripheral neuropathy in non-Hodgkin's lymphoma patients receiving vincristine with and without aprepitant/fosaprepitant.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2019
Same author

Direct oral anticoagulants in patients with cancer.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2019
Same author

FLT3 inhibitors in acute myeloid leukemia: Current and future.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2018

Related Experiment Video

Updated: Mar 8, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.9K

Drug Interaction Database Sensitivity With Oral Antineoplastics: An Exploratory Analysis.

John B Bossaer1, Christan M Thomas1

  • 1Bill Gatton College of Pharmacy, East Tennessee State University, Johnson City; and James H. Quillen VA Medical Center, Mountain Home, TN.

Journal of Oncology Practice
|January 18, 2017
PubMed
Summary

Lexi-Interact and Drugs.com showed 95% sensitivity in detecting oral antineoplastic drug interactions. Other databases varied, highlighting the need for multiple resources and clinical judgment in oncology practice.

More Related Videos

Assessing Specificity of Anticancer Drugs In Vitro
09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

9.9K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.2K

Related Experiment Videos

Last Updated: Mar 8, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.9K
Assessing Specificity of Anticancer Drugs In Vitro
09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

9.9K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.2K

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Pharmacy

Background:

  • The increasing use of oral antineoplastics (OAs) in cancer treatment necessitates careful management of drug interactions.
  • Electronic databases are commonly used to screen for these interactions, but their reliability with OAs is not well-established.

Purpose of the Study:

  • To evaluate the sensitivity of widely used drug interaction databases in identifying interactions involving oral antineoplastics.
  • To compare the performance of different electronic resources in detecting OA drug interactions.

Main Methods:

  • A curated list of 20 drug interactions with OAs was developed by oncology pharmacy specialists.
  • The sensitivity of MicroMedex, Facts & Comparisons, Lexi-Interact, and Epocrates was assessed.
  • Drugs.com was included as a patient-accessible database surrogate.

Main Results:

  • Lexi-Interact and Drugs.com demonstrated the highest sensitivity at 95%.
  • Epocrates showed 90% sensitivity, while MicroMedex and Facts & Comparisons had 70% sensitivity.
  • A statistically significant difference in sensitivity distribution was observed among the databases (P = .016).

Conclusions:

  • There is significant variability in the sensitivity of drug interaction databases for oral antineoplastics.
  • Oncology clinicians should utilize multiple resources and clinical judgment, rather than relying on a single database.
  • Further research is recommended to improve the accuracy of drug interaction detection systems for OAs.